An essential webinar for preclinical scientists that wish to learn how to integrate hemodynamic, respiratory and neurological measurements to study multiple biological systems simultaneously while benefiting from more efficient data collection and workflow in the laboratory.

The drive to increase efficiency while decreasing animal numbers is leading more researchers to employ “combination study designs”, where multiple physiologic endpoints are simultaneously collected per subject. When combining multiple physiologic endpoints researchers have immediate access to more data, and by extension, deeper insights per animal and per study. However, as with any novel approach combination studies have the potential for complexity.

In this case study webinar sponsored by Data Sciences International, Dr. Brian Roche of Charles River Laboratories and Jason Payseur of GlaxoSmithKline discuss advantages and challenges pertaining to the combination of physiologic monitoring technologies to collect respiratory, cardiovascular and neurological endpoints from a single animal subject.

Specifically, Dr. Roche presents an evaluation of the AllayTM restraint technology utilized in DSI Respiratory solutions versus other commonly used methods. Complimented with implantable telemetry, Dr. Roche shows how he examined the effects of each method on various cardiopulmonary parameters and discusses the benefits and challenges associated with the use of the AllayTM restraint. Jason Payseur presents his assessment of a novel rodent model that examines cardiovascular, respiratory and neurobehavioral endpoints at the same time. He investigates the surgical feasibility of this model and tests its reliability in measuring multiple physiologic endpoints using tool compounds with known physiological effects, caffeine and chlorpromazine.

Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.

Resources

To retrieve a PDF copy of the presentation, click on the link below the slide player. From this page, click on the “Download” link to retrieve the file.

Presenters

Director of Safety Pharmacology
Charles River Laboratories

Dr. Roche received his doctorate in cardiovascular physiology from The Ohio State University in 2000, where he continued as a postdoctoral fellow until 2002. Dr. Roche worked in safety pharmacology at Quintiles QTest Labs and Battelle Memorial Institute before accepting the director of safety pharmacology position at WIL Research in 2014. Following the 2016 acquisition of WIL Research by Charles River, Dr. Roche has contributed to the scientific collaboration and establishment of best practices across all Charles River Laboratories' safety pharmacology sites. Throughout his career, Dr. Roche has focused on mechanistic follow-up studies to ICH S7A core battery to de-risk drugs in development, as well as supplemental studies to include renal, gastrointestinal and autonomic nervous systems. His research has included toxicological and pharmacological evaluations of compounds from early in vivo discovery/lead optimization through IND enabling studies. Dr. Roche’s extensive experience in cardiovascular, respiratory and central nervous system safety pharmacology research provides him with a unique ability to support both alignment of best practices and scientific innovation.

Senior Scientist
GlaxoSmithKline

Production Partner

Data Sciences International

Data Sciences International (DSI) is the leader in preclinical physiological monitoring offering telemetry, instrumentation, software and services to help advance science. Industries served include: Pharmaceuticals, Academia, Contract Research Organizations, Biological and Chemical Defense, Medical Devices, Government, and Biotechnology.

Harvard Bioscience, Inc.

Harvard Bioscience is a global leader in the manufacturing and distribution of solutions to advance life science research. For over 110 years, we have served the changing needs of life scientists in over 100 countries. Our expanding portfolio of brands include instruments for organ and animal research, cell analysis, molecular biology, fluidics, and laboratory consumables.

Additional Content From Data Sciences International

Additional Content From Harvard Bioscience, Inc.

Related Content